SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on May 25, 2017, reporting events occurring on May 24, 2017. The filing details the execution of a First Amendment to a Securities Purchase Agreement and the closing of the second tranche of a private placement of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of unregistered common stock under Section 4(a)(2) and Rule 506 of Regulation D.
- Tranche Closed: Second Tranche of a three-tranche agreement.
- Shares Issued: 6,303,814 shares of Common Stock.
- Price Per Share: $2.60.
- Total Proceeds (Second Tranche): Approximately $16.4 million (calculated as 6,303,814 shares * $2.60).
- Total Agreement Capacity: Up to $25.0 million across three tranches ($3.5 million, $16.4 million, and $5.1 million).
- Financial Metrics: The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the amendment of the Securities Purchase Agreement dated April 26, 2017, to allocate specific share quantities for the second and third tranches among the purchasers. Consequently, the Company successfully closed the second tranche, raising approximately $16.4 million in equity capital.
Outlook, Risks, and Unusual Items
Management Commentary: The Company issued a press release on May 25, 2017, announcing the closing of the Second Tranche. The shares were sold to accredited investors for investment purposes only, not for resale or distribution.
Risks and Contingencies: The securities sold are not registered under the Securities Act of 1933. The transaction relies on exemptions from registration requirements. No specific forward-looking guidance or risk factors beyond standard private placement disclosures are detailed in this specific filing text.
Investor Verification Checklist
- Verify the full text of the First Amendment to the Securities Purchase Agreement (Exhibit 99.1) for specific allocation details among purchasers.
- Confirm the use of proceeds from the $16.4 million raised in the second tranche via the Company's press release (Exhibit 99.2) or subsequent filings.
- Monitor the status of the remaining tranches (first tranche of $3.5 million and third tranche of $5.1 million) to determine if the full $25.0 million capacity will be utilized.
- Review the Company's latest 10-K or 10-Q for comprehensive financial health metrics, as this 8-K does not contain operational financial data.